drugset / Trial / NCT04367675
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
Phase 1
Active not recruiting
44 enrolled
Abramson Cancer Center at Penn Medicine
Inovio Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-5401 | Other / unclassified | — | — |
| Subject | Rocakinogene Sifuplasmid | Vaccine | — | — |